REQUEST A DEMO
Total
USD $0.00
Search more companies

CHO Pharma, Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: CHO Pharma, Inc. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

CHO Pharma, Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. The company was founded in 2013 and is headquartered in Taipei, Taiwan.

Headquarters
7F., No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist
Taipei City; Taipei City;

Contact Details: Purchase the CHO Pharma, Inc. report to view the information.

Website: http://www.chopharma.com

Basic Information
Total Employees:
Purchase the CHO Pharma, Inc. report to view the information.
Outstanding Shares:
Purchase the CHO Pharma, Inc. report to view the information.
Financial Auditors:
Purchase the CHO Pharma, Inc. report to view the information.
Incorporation Date:
March 08, 2013
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
15.48%
Purchase this report to view the information.
3.3%
Purchase this report to view the information.
1.8%
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Cho Pharma Usa, Inc (United States)
100%
Company Performance
Financial values in the chart are available after CHO Pharma, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
23.95%
EBITDA
22.73%
Net Profit (Loss) for the Period
33.71%
Total assets
109.78%
Total equity
125.23%
Return on Equity (ROE)
8.33%
Quick Ratio
17.38%
Cash Ratio
-1.21%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?